Preclinical oncology studies have demonstrated a rapid decrease in FLT uptake in response to a range of anti–cancer therapies, including chemotherapies [29,30], radiotherapies [31,32], and some protein kinase inhibitors [33,34,35,36]. The gene discussed is WEE1; the disease is cancer.